Latest Insider Transactions at Turning Point Therapeutics, Inc. (TPTX)
This section provides a real-time view of insider transactions for Turning Point Therapeutics, Inc. (TPTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Turning Point Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Turning Point Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2020
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
7,000
-0.27%
|
$413,000
$59.05 P/Share
|
|
Jan 28
2020
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
7,000
-0.41%
|
$406,000
$58.4 P/Share
|
|
Jan 27
2020
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
7,000
-0.27%
|
$399,000
$57.64 P/Share
|
|
Jan 15
2020
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.65%
|
$609,500
$53.34 P/Share
|
|
Jan 14
2020
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
18,500
-0.69%
|
$980,500
$53.27 P/Share
|
|
Jan 13
2020
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
18,500
-0.68%
|
$980,500
$53.27 P/Share
|
|
Jan 10
2020
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
18,500
-0.33%
|
$1,036,000
$56.95 P/Share
|
|
Dec 30
2019
|
Jingrong Jean Cui Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
16,864
+1.86%
|
$84,320
$5.12 P/Share
|
|
Dec 27
2019
|
Jingrong Jean Cui Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
38,080
+2.13%
|
$152,320
$4.16 P/Share
|
|
Dec 20
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.41%
|
$724,500
$63.35 P/Share
|
|
Dec 19
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
18,500
-0.48%
|
$1,128,500
$61.09 P/Share
|
|
Dec 18
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
18,500
-0.47%
|
$1,091,500
$59.1 P/Share
|
|
Dec 17
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
18,500
-0.46%
|
$1,128,500
$61.55 P/Share
|
|
Dec 16
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.19%
|
$667,000
$58.14 P/Share
|
|
Dec 13
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.37%
|
$644,000
$56.18 P/Share
|
|
Dec 12
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.37%
|
$609,500
$54.0 P/Share
|
|
Dec 11
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.37%
|
$609,500
$53.53 P/Share
|
|
Dec 10
2019
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
216
+6.68%
|
$6,696
$31.13 P/Share
|
|
Dec 10
2019
|
Athena Countouriotis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
706
+3.02%
|
$21,886
$31.13 P/Share
|
|
Dec 10
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.36%
|
$621,000
$54.7 P/Share
|
|
Dec 09
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
11,500
-0.27%
|
$632,500
$55.6 P/Share
|
|
Dec 06
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
50,890
-2.29%
|
$2,544,500
$50.84 P/Share
|
|
Dec 05
2019
|
Jingrong Jean Cui Director |
SELL
Open market or private sale
|
Indirect |
56,110
-1.61%
|
$2,861,610
$51.95 P/Share
|
|
Sep 10
2019
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
177,777
+7.57%
|
$7,999,965
$45.0 P/Share
|
|
Sep 10
2019
|
Athena Countouriotis President & CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+31.25%
|
$450,000
$45.0 P/Share
|
|
Sep 10
2019
|
Yi Larson EVP & Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,222
+50.0%
|
$99,990
$45.0 P/Share
|
|
Sep 10
2019
|
Simeon George Director |
BUY
Open market or private purchase
|
Indirect |
177,777
+7.57%
|
$7,999,965
$45.0 P/Share
|
|
Jun 27
2019
|
Jingrong Jean Cui Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
54,220
+6.09%
|
$271,100
$5.12 P/Share
|
|
May 14
2019
|
Cormorant Asset Management, LP > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
23,268
+0.74%
|
$46,536
$2.19 P/Share
|
|
Apr 22
2019
|
Cormorant Asset Management, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+11.43%
|
$7,200,000
$18.0 P/Share
|
|
Apr 22
2019
|
Athena Countouriotis President & CEO |
BUY
Open market or private purchase
|
Direct |
12,000
+50.0%
|
$216,000
$18.0 P/Share
|
|
Apr 22
2019
|
Brian Lee Baker SVP of Finance and Admin. |
BUY
Open market or private purchase
|
Direct |
2,800
+50.0%
|
$50,400
$18.0 P/Share
|
|
Apr 22
2019
|
Simeon George Director |
BUY
Open market or private purchase
|
Indirect |
325,000
+14.02%
|
$5,850,000
$18.0 P/Share
|
|
Apr 22
2019
|
Simeon George Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
360,000
+15.08%
|
$6,480,000
$18.0 P/Share
|
|
Apr 22
2019
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
60,000
+3.36%
|
$1,080,000
$18.0 P/Share
|
|
Apr 22
2019
|
Lu Hongbo Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
360,000
+15.08%
|
$6,480,000
$18.0 P/Share
|
|
Apr 22
2019
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|
|
Apr 22
2019
|
Glaxosmithkline PLC Director |
BUY
Open market or private purchase
|
Indirect |
325,000
+14.02%
|
$5,850,000
$18.0 P/Share
|
|
Apr 22
2019
|
Glaxosmithkline PLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,667,550
+37.35%
|
-
|